C3 Pancreatic Cancer Group Annual Reports

C3-Pancreatic Cancer Research Group

2021-2022 Annual Report

 

 

September 20, 2021 (Virtual)

• PET imaging of newly identified metabolic alterations induced by STING activation in tumor and immune cells

By Caius Radu

UC Los Angeles

 

October 18, 2021 (Virtual)

• Mechanisms and consequences of pancreatic cancer stromal evolution

By Mara Sherman

Oregon Health & Science University

 

November 15, 2021 (Virtual)

• Cellular Plasticity and Its Consequences During Pancreatic Progression

By Howard Crawford

Henry Ford Cancer Institute

 

January 24, 2022 (Virtual)

• Cell identities lost and found in pancreatic cancer

By Charles Murtaugh

University of Utah

 

February 28, 2022 (Virtual)

• Cellular crosstalk and signaling driving the development of pancreatic cancer

By Peter Storz

Mayo Clinic Jacksonville

 

 

March 21, 2022 (Virtual)

• Determinants of immune resistance in pancreatic cancer

By Gregory Beatty

University of Pennsylvania Perelman School of Medicine

 

 

 

C3-Pancreatic Cancer Research Group

2020-2021 Annual Report

September 21, 2020

· Emerging role of the transcription factor XBP1 in pancreatic cancer development

By Aurelia Lugea

Cedar Sinai

November 16, 2020

· Role of Spleen tyrosine kinase in pancreatic adenocarcinoma progression

By Shweta Joshi

UC San Diego

January 25, 2021

· Targeting Metabolic Crosstalk in Pancreatic Cancer

By Christopher Halbrook

UC Irvine

February 22, 2021

· Exosome and Exomere Biomarkers for Early Cancer Detection

By David Lyden

Cornell University

March 15, 2021

· Molecular Mechanisms and Prevention of Obesity-Driven Tumor Progression

By Zobeida Cruz-Monserrate

The Ohio State University Wexner Medical Center

April 19, 2021

· Translating Translation in Pancreatic Cancer

By Christine Chio

Columbia University Irving Medical Center

May 17, 2021

· Macropinocytosis as a mechanism for drug resistance in tumors

By Aimee Edinger

UCI School of Biological Sciences

June 21, 2021

· Statins in Obesity-Promoted Pancreatic Cancer

By Guido Eibl

David Geffen School of Medicine at UCLA

C3-Pancreatic Cancer Research Group

2019-2020 Annual Report

September 16th, 2019

· The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice

By Dannielle Engle

Salk Institute

October 21st, 2019

· Protein Kinase C Unbalanced: Loss-of-Function in Cancer

By Alexandra Newton

UC San Diego

November 18th, 2019

· Copy Number Alterations in Ovarian Cancer Connecting Chemoresistance and Immune Evasion

By David Schlaepfer

UC San Diego

February 24th, 2020

· Hijacking Kras Addicted Glycolysis by Peptide-Directed Drug Delivery

By Gregory Botta

UC San Diego

C3-Pancreatic Cancer Research Group

2018-2019 Annual Report

September 6th, 2018

· ROR-gamma is a novel regulator of stem cell signals in pancreatic cancer

By Nikki K. Lytle

UC San Diego

October 4th, 2018

· Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

By Yi Liu

Wellspring Biosciences Inc.

November 1st, 2018

· ABCs of Immunotherapy in Solid Tumors: Agents, Biomarkers, Cells

By Sandip Patel

UC San Diego

February 7th, 2019

· Pancreatic cancer is a disease of aging - Should we/can we study it as such?

By Peter Adams

Sanford Burnham Prebys Medical Discovery Institute

March 7th, 2019

· Functional Identification and Therapeutic Targeting of Neoantigens in Solid Tumors

By Aaron M. Miller

Moores Cancer Center

April 4th, 2019

· Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

By Herve Tiriac

Moores Cancer Center

May 2nd, 2019

· Exploring glycosaminoglycans as targets for effective treatment of Pancreatic cancer

By Thomas Mandel Clausen Visiting Associate Professor

UC San Diego

June 6th, 2019

· Genome-wide microRNA and CRISPR Screens for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers

By Tariq Rana

Moores Cancer Center

C3-Pancreatic Cancer Research Group

2017-2018 Annual Report

 

 

September 7th, 2017

-          Transcriptional Reprogramming with Minnelide in Pancreatic Cancer

By Hitendra Patel

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

October 5th, 2017

-          The ID3/E2A Axis in PDA and Pancreatitis

By Pamela Itkin-Ansari

Sanford Burnham Prebys Medical Discovery Institute

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

November 2nd, 2017

-          Molecular Engineering of Macrophages for Cancer Therapies

By Peter Yingxiao Wang

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

 

January 4th, 2018

 

-          Pancreatic tuft cells resolve injury and restrain tumorigenesis

By Kathleen DelGiorno

Salk Institute

 

- Location: Sanford Burnham Prebys Medical Discovery Institute

 

 

February 1st, 2018

 

-          Targeted drug delivery to pancreatic cancer and other solid tumors

By Erkki Ruoslahti

Sanford Burnham Prebys Medical Discovery Institute

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

 

March 1st, 2018

 

- Attacking KRAS-driven Lung and Pancreatic Cancer

By David Cheresh

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

April 5th, 2018

 

-          Small Molecule Modulators of Autophagy for the Treatment of Pancreatic Cancer

By Allison Limpert on behalf of Nicholas Cosford

Sanford Burnham Prebys Medical Discovery Institute

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

June 7th, 2018

 

-          Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy 

(I-PREDICT) in Patients with Lethal Malignancies

By Jason Sicklick

UC San Diego

 

-          Location: Sanford Children’s Health Research Center

 

C3-Pancreatic Cancer Research Group

2016-2017 Annual Report

 

September 8th, 2016

-  C3-PCRG - Goals and opportunities

Dr. Andrew Lowy, Professor and Director of Surgical Oncology, UCSD

 

-          Autophagy-Independent Tumor Suppressor Role of p62 in the Stroma

By Jorge Moscat, PhD

Sanford Burnham Prebys Medical Discovery Institute

-          Location: Sanford Burnham Prebys Medical Discovery Institute

October 6th, 2016

-          G Protein-Coupled Receptors as Contributors and Targets in Pancreatic Cancer

By Paul Insel, MD

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

November 3rd, 2016

-          Insight into targeting of pancreatic cancer with the co-deletion of CDNK2A/MTAP :

Lessons from melanoma

By Ze'ev Ronai, PhD & Hyungsoo Kim, PhD

Sanford Burnham Prebys Medical Discovery Institute

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

 

January 12th, 2017

 

C3- PCRG’s first translational meeting where basic scientists and clinicians will have the opportunity to look into patient presentations, treatment, imaging, molecular study, trial details, fellow presentations, and literature review

 

-          Case Studies of Targeting DNA Damage Repair

By Andrew Lowy, MD & Paul Fanta, MD

UC San Diego

 

- Location: UC San Diego’s Moores Cancer Center

 

 

February 2nd, 2017

 

-   Exploiting altered proteolytic activity for detection of pancreatic cancer

By Anthony J. O’Donoghue, PhD

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

 

March 2nd, 2017

 

-          Irreversible Electroporation (IRE) for Treatment of Pancreatic Cancer

By Rebekah R. White, MD, FACS

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

April 6th, 2017

 -         Rapid Isolation and Detection of Pancreatic Cancer Exosome Biomarkers

By Michael Heller, PhD

UC San Diego

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

May 4th, 2017

 

- PEGPH20: Improving Therapeutic Efficacy by Targeting the Tumor Microenvironment

By Curt Thompson - Senior Director of the Pharmacology group

Halozyme Therapeutics, Inc.

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

June 1st, 2017

 

- Investigating the role of hypoxia inducible factors in Pancreatic Ductal Adenocarcinoma

By Anindya Bagchi, Ph.D. 

Sanford Burnham Prebys Medical Discovery Institute

 

-          Location: Sanford Burnham Prebys Medical Discovery Institute

 

 

C3-Pancreatic Cancer Research Group

2015-2016 Annual Report

 

June 4th

-  Welcome: Dr. Garth Powis, Professor and Director of Sanford-Burnham Cancer Center

-  C3-PCRG - Goals and opportunities: Dr. Andrew Lowy, Professor and Director of

   Surgical Oncology, UCSD

 

-  Pancreatic cancer: Where do we stand?

   Andrew Lowy, MD

 

- Tumor-stroma interactions in pancreatic cancer

   Garth Powis, PhD

 

July 9th

-  Stem Cell Signals in Pancreatic Cancer Progression and Therapy Resistance

   Tannishtha Reya, PhD

   UC San Diego Moores Cancer Center

 

-  Primer on Pancreatic Pathology: A Pathologist’s Perspective

   Mark Valasek, MD, PhD

   UC San Diego Moores Cancer Center

 

August 13th

-  A novel paradigm for EGFR inhibition in pancreatic cancer'

  Tony Reid, MD, PhD

   UC San Diego Moores Cancer Center

 

- Keeping up with supply and demand: The role of nutrient scavenging in pancreatic                                      

  Cancer

  Cosimo Commisso, PhD

  Sanford Burnham Prebys Medical Discovery Institute

 

September 3rd

- Vitamin D: Shining Light on Pancreatic Cancer

  Ron Evans, PhD

  Salk Institute

 

- Importance of Local Tumor Control in Pancreatic Cancer

  Jim Murphy, MD

  UC San Diego Moores Cancer Center

 

October 8th

- Developing Unique Tumor-Targeted Radiosensitization Strategies

  Sunil Advani, MD

  UC San Diego Moores Cancer Center

 

- A Novel Biomarker Panel Examining Response to Adjuvant Pancreatic Cancer Therapy

  Gregory Heestand, MD

  UC San Diego Moores Cancer Center

 

November 5th

- Current Efforts and Opportunities in Small Molecule Drug Discovery

  Michael Jackson, Ph.D. and Chris Hassig, Ph.D.

  Sanford Burnham Prebys Medical Discovery Institute

 

- Hereditary Pancreatic Cancer Syndromes: Update on genetic testing and clinical 

  Management

  Lisa Madlensky, PhD, CGC

  UC San Diego Moores Cancer Center

 

January 7th

- Cellular Origins of Pancreatic Ductal Adenocarcinoma

  Maike Sander, MD

  UC San Diego Moores Cancer Center

 

- Pancreatic Cystic Neoplasm Management

  Thomas Savides, MD

  UC San Diego Moores Cancer Center

 

February 4th

-  p62/SQSTM1 Accumulation Links Chronic Tissue Damage to Malignant Progression in 

  Liver and Pancreas

  Michael Karin, PhD

  UC San Diego Moores Cancer Center

 

- The MCC Biorepository and Tissue Technology Shared Resources: A six month 

  Appraisal

  Alfredo Molinolo, MD, PhD

  UC San Diego Moores Cancer Center

 

 

March 3rd

- New Approaches to Targeting Stellate Cell Reprogramming and Understanding Ras

  Geoffrey M. Wahl, Ph.D.

              The Salk Institute

 

- Pancreatic Cancer: After 2000 years, Progress

  Darren Sigal, MD

  Scripps Health

 

April 7th

- Analyzing the Secretomes of Pancreatic Tumor and Stromal Cells to Identify Targetable 

  Factors Involved in Paracrine Signaling in the Tumor Microenvironment

  Tony Hunter, Ph.D.

  The Salk Institute

 

- Fluorescence-Guided Surgery for Pancreatic Cancer

  Michael Bouvet, MD, FACS

  Moores Cancer Center

 

May 5th

- Macrophage signaling drives pancreatic cancer

  Judith Varner, PhD

  Moores Cancer Center

 

- Clinical utility of oncolytic viruses in pancreas cancer

  Kaitlyn Kelly, MD

  Moores Cancer Center

 

June 2nd

- The Hypusine/eIF5A Cascade Promotes the Malignant Progression of Pancreatic

  Cancer

  Ken Fujimura, PhD

  Moores Cancer Center

 

- Update on National Clinical Trials Network Studies in Pancreatic Cancer

  Andrew Lowy, MD

  Moores Cancer Center